Published in Transplantation on March 15, 2009
Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. Am J Transplant (2016) 0.89
Cirrhotic cardiomyopathy. World J Gastroenterol (2015) 0.84
Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol (2015) 0.82
The end-organ impairment in liver cirrhosis: appointments for critical care. Crit Care Res Pract (2012) 0.82
High early cardiovascular mortality after liver transplantation. Liver Transpl (2014) 0.82
Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis. J Cardiovasc Magn Reson (2010) 0.79
Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival. Curr Opin Organ Transplant (2016) 0.78
Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis. BMC Gastroenterol (2014) 0.78
A meta-analysis of complications following deceased donor liver transplant. Am J Surg (2014) 0.77
Cardiovascular changes in cirrhosis: pathogenesis and clinical implications. Saudi J Gastroenterol (2010) 0.76
Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation. World J Gastroenterol (2014) 0.76
Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease. Int J Cardiovasc Imaging (2015) 0.76
Stroke volume response to liver graft reperfusion stress in cirrhotic patients. World J Surg (2014) 0.76
Hemodynamics in the immediate post-transplantation period in alcoholic and viral cirrhosis. World J Gastroenterol (2010) 0.76
Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients. World J Hepatol (2015) 0.76
Significance of Abnormal Myocardial Perfusion Scans in Candidates for Orthotopic Liver Transplantation. J Tehran Heart Cent (2017) 0.75
Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World J Transplant (2016) 0.75
Coronary Computed Tomography Angiography in Combination with Coronary Artery Calcium Scoring for the Preoperative Cardiac Evaluation of Liver Transplant Recipients. Biomed Res Int (2017) 0.75
Preoperative cardiovascular investigations in liver transplant candidate: An update. Indian J Anaesth (2016) 0.75
Ventricular fibrillation in a patient with tachycardia-induced cardiomyopathy after liver transplantation. Korean Circ J (2013) 0.75
Perioperative Cardiovascular Evaluation for Orthotopic Liver Transplantation. Dig Dis Sci (2016) 0.75
A Point-based Prediction Model for Cardiovascular Risk in Orthotopic Liver Transplantation: The CAR-OLT Score. Hepatology (2017) 0.75
Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 3.64
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol (2010) 2.39
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl (2012) 2.26
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol (2011) 1.79
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol (2004) 1.66
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl (2009) 1.55
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol (2008) 1.50
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem (2008) 1.47
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
Journals' impact and pecking order: tyranny and tyrannosaurs. Liver Int (2012) 1.39
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet (2012) 1.27
The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol (2007) 1.25
Cirrhotic cardiomyopathy. Semin Liver Dis (2008) 1.21
Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol (2006) 1.19
Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol (2010) 1.18
The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis (2002) 1.13
Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int (2008) 1.13
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int (2007) 1.11
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10
Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol (2013) 1.10
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol (2006) 1.06
Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol (2011) 1.05
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.02
Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol (2005) 1.02
Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology (2009) 1.01
How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int (2013) 1.01
Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology (2013) 1.01
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol (2005) 0.99
The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol (2007) 0.98
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int (2008) 0.98
Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Amiodarone hepatotoxicity. Curr Vasc Pharmacol (2008) 0.98
The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol (2002) 0.97
Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol (2004) 0.97
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Polycystic liver disease: experience at a teaching hospital. Am J Gastroenterol (2005) 0.96
A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol (2009) 0.96
Prevalence of occult gastrointestinal bleeding in celiac disease. Clin Gastroenterol Hepatol (2006) 0.96
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Cirrhotic cardiomyopathy. Gastroenterol Clin Biol (2002) 0.95
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95
Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care (2007) 0.95
Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) (2002) 0.93
Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93
Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev (2011) 0.93
Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS One (2013) 0.93
Pregnancy outcomes among liver transplant recipients in the United States: a nationwide case-control analysis. Liver Transpl (2010) 0.93
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer (2015) 0.92
Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int (2013) 0.92
Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol (2006) 0.92
ABO-incompatible liver transplantation for critically ill adult patients. Transpl Int (2007) 0.91
Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90
Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep (2013) 0.89
Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int (2007) 0.88
Cirrhotic cardiomyopathy. Ann Hepatol (2006) 0.88
Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl (2010) 0.88
Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain. World J Gastroenterol (2006) 0.88
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov (2013) 0.87
Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int (2008) 0.85
Is surgical resection still the treatment of choice for early hepatocellular carcinoma? J Surg Oncol (2011) 0.85
Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology (2003) 0.85
Cheating in scientific publishing: the scourge must stop! Liver Int (2008) 0.85
Population-based review of the outcomes following hepatic resection in a Canadian health region. Can J Surg (2009) 0.85
Concurrence of primary biliary cirrhosis and antiphospholipid antibody syndrome. Am J Gastroenterol (2004) 0.84
Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis (2013) 0.84
B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol (2013) 0.84
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol (2013) 0.83
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol (2003) 0.83
Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis (2007) 0.83
Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol (2003) 0.83
Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model. Scand J Gastroenterol (2005) 0.82
Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol (2008) 0.82
Cholangiocarcinoma: has there been any progress? Can J Gastroenterol (2010) 0.82
What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology (2005) 0.81
Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol (2005) 0.81
Simultaneous liver and kidney transplants: optimizing use of this double resource. Transplantation (2011) 0.81